Clinical Trial Risk in Hepatitis C: Endpoint Selection and Drug Action

Table 1

The number of small molecule and biologic drugs associated with known molecular targets.

Target	Small molecule	Biologic	Mechanism of action
HCV NS5B polymerase	32	3	Viral inhibitor
HCV NS3/4A serine protease	19	2	Viral inhibitor
HCV NS5A protein	17	1	Viral inhibitor
Mechanisms unclear/unknown	9	3	Other
Immune adjuvants	2	10	Immunotherapy
Viral replication inhibitor	2	2	Viral inhibitor
Toll-like receptor 9 agonist (TLR9)	0	4	Immunotherapy
Toll-like receptor 7 agonist (TLR7)	0	2	Immunotherapy
Cyclophilin	2	0	Host inhibitor
Blocks viral entry	2	0	Host inhibitor
Caspase inhibitor	2	0	Host inhibitor
Interferon	0	6	Immunotherapy
HCV internal ribosome entry site (IRES) in 5′UTR	1	1	Viral inhibitor
Inosine monophosphate dehydrogenase	1	0	Host inhibitor
Alpha-glucosidase 1	1	0	Host inhibitor
Monoclonal antibodies	0	5	Immunotherapy
Mature miR-122 (a liver microRNA)	0	1	Host inhibitor